- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
Vanda's Hetlioz is not the prettiest approval story, but over 350 prescriptions since February for a $60,000 orphan drug is not horrible. It'll need 1,500 prescriptions to break even.
Raptor released positive phase 3 data for its Huntington's treatment in February, but since then little has happened. The share price is now depressed, presenting a good entry point.
Before anything, there is the money supply. Stocks can rise only if the money supply is increasing. Right now it isn't.
When a country defaults, it usually repegs to the U.S. dollar in order to re-establish a basic economy. But if the U.S. itself defaults, it can't peg to the dollar.
The monetary base just crossed the $4 trillion mark for the first time ever. Price inflation is heating up and becoming more obvious.
Musk's move to open Tesla's patent portfolio appears to have been a politically savvy move to pressure politicians into letting him sell directly to consumers.
Are you looking for an inflation hedge but not interested in gold? Potash has worked as a leveraged inflation play before, and it may again.
Janet Yellen's press conference this week forgot to mention one big thing: the over $2.5 trillion sitting in excess reserves at the Federal Reserve.